Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Nov 14, 2019

SELL
$16.91 - $36.27 $18.3 Million - $39.3 Million
-1,083,598 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$31.0 - $36.3 $4.8 Million - $5.62 Million
-154,891 Reduced 12.51%
1,083,598 $38.6 Million
Q1 2019

May 15, 2019

BUY
$31.58 - $46.35 $3.29 Million - $4.82 Million
104,075 Added 9.17%
1,238,489 $41.6 Million
Q2 2018

Aug 14, 2018

BUY
$46.25 - $104.45 $21.5 Million - $48.7 Million
465,922 Added 69.7%
1,134,414 $55.4 Million
Q1 2018

May 15, 2018

SELL
$57.4 - $108.44 $40.1 Million - $75.8 Million
-698,679 Reduced 51.1%
668,492 $71 Million
Q4 2017

Feb 14, 2018

SELL
$23.02 - $60.5 $20.9 Million - $54.9 Million
-907,490 Reduced 39.9%
1,367,171 $81.6 Million
Q3 2017

Nov 14, 2017

BUY
$17.79 - $24.0 $40.5 Million - $54.6 Million
2,274,661
2,274,661 $54.6 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $154M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Bridger Management, LLC Portfolio

Follow Bridger Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridger Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridger Management, LLC with notifications on news.